Cancer(multi-cancer)
Conditions
Interventions
Gold Standard:The gold standard for diagnosis of "malignant tumor" is the pathological diagnosis of biopsy or operation. If the subject suspects "malignant tumor" but there is no biopsy pathology or s
Index test:"YiDiXue" multi-cancer early detection kit (Shenzhen Kerida Health Technology Co., LTD.).
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Confirmed case studies: (1) Patients diagnosed with primary malignant tumor by preoperative imaging, gastroenteroscopy or biopsy pathology; (2) Patients who have the ability to understand informed consent and consent to participate in the trial (informed consent is subject to approval by an independent ethics committee and informed consent from patients prior to the commencement of any study-related process; (3) Patients with untreated primary malignancies. 2. Normal population: (1) Age >18 years old, male or female; (2) Subjects who have the ability to understand informed consent and consent to participate in the program (informed consent requires approval by an independent ethics committee and informed consent from the patient prior to the commencement of any study-related process).
Exclusion criteria
Exclusion criteria: 1. Confirmed case study: (1) Patients with primary malignant tumor considered before surgery, but not diagnosed as primary malignant tumor by pathology after surgery; (2) Patients identified as non-malignant tumors after surgery; (3) Patients with other severe liver and kidney function impairment, diabetes, severe infection and cardiac insufficiency; (4) The treated physician considered that the patient's actual condition was not suitable for the study. 2. Normal population: (1) The presence of a known malignancy in the body (has been diagnosed with a malignancy and has not or cannot be surgically removed); (2) Our research group believes that the actual condition of the subjects is not suitable for participating in this project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total sensitivity;Total specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total positive predictive value;Total negative predictive value;Total accuracy rate (total coincidence rate); | — |
Countries
China
Contacts
Public ContactLai Yongqing
Peking University Shenzhen Hospital
Outcome results
None listed